Proactive research analyst Emma Ulker discusses MaxCyte's () results for the year to December 2019.
Ulker says the firm delivered a consensus-beating 30% uplift in full-year 2019 revenues to US$21.6mln - underpinned by the release of milestone payments from its commercial partners as programmes advanced through clinical studies and by a 25% five-year revenue compound annualised growth rate (CAGR).
Click here to read the latest research update on MaxCyte : Milestones a key contributor to 30% top line growth
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE